

Global Antibribery & Anticorruption Policy

Effective: 17 June 2019

Purpose

At BD we do what is right. Acting with integrity is critical to ensuring our success and protecting our reputation as we strive to *advance the world of health*. An important part of achieving our objectives is interacting and collaborating with government officials (“GOs”), healthcare professionals (“HCPs”), and healthcare organizations (“HCOs”). Collaboration with GOs, HCPs, and HCOs in both the public and private sector must be ethical, compliant, and must not have (*or appear to have*) an improper influence on government official decisions, medical judgment, purchasing decisions, or product recommendations. We must ensure that such interactions do not involve bribery, corruption, or other improper behavior. For these reasons, we do not offer, promise, provide, authorize, or accept improper payments, and we record all payments accurately.

Scope

This policy applies to Becton, Dickinson and Company, its divisions, and majority-owned or controlled subsidiaries (“BD”).

All BD associates and agents must adhere to this policy.

If a country has laws that impose stricter standards, the stricter standards must govern activities of BD associates. Local BD policy should be developed and implemented to ensure BD associates are familiar with the stricter standards.

Policy

General requirements

Associates and external business partners must conduct their activities in full compliance with all applicable antibribery and anticorruption laws, including local laws and industry codes in the countries where BD operates, as well as laws with cross-border implications such as the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act.

Associates shall not make improper payments.

Associates may not offer, promise, provide, or authorize giving anything of value—directly or indirectly—to anyone in exchange for an improper business advantage. BD also prohibits giving anything that may have value to a GO in order to: (1) encourage the GO to perform or fail to perform any act; or (2) to use his or her influence to affect or influence a government or governmental entity’s decision, including procurement decisions. BD may be liable for improper payments made by associates.




Approval


Author:

Approver:

By: Michelle T. Quinn

By: Vincent A. Forlenza

Name: 

Name: 

Title: *SVP, Chief Ethics & Compliance Officer,
Chief Regulatory Counsel*

Title: *Chairman & Chief Executive
Officer*

